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Pancreatic islet inflammation contributes to the failure of b cell insulin secretion during obesity-associated type 2 diabetes. However, little is known about the role of resident immune cells in this context or in homeostasis. Dalmas and colleagues demonstrate that mesenchymal-cell-derived IL-33 orchestrates an immunometabolic crosstalk in pancreatic islets and that this crosstalk promotes insulin secretion. They show that islet-resident group 2 innate lymphoid cells stimulate retinoic acid production from local myeloid cells and that retinoic acid in turn acts on b cells.
SUMMARY
Pancreatic-islet inflammation contributes to the failure of b cell insulin secretion during obesity and type 2 diabetes. However, little is known about the nature and function of resident immune cells in this context or in homeostasis. Here we show that interleukin (IL)-33 was produced by islet mesenchymal cells and enhanced by a diabetes milieu (glucose, IL-1b, and palmitate). IL-33 promoted b cell function through islet-resident group 2 innate lymphoid cells (ILC2s) that elicited retinoic acid (RA)-producing capacities in macrophages and dendritic cells via the secretion of IL-13 and colony-stimulating factor 2. In turn, local RA signaled to the b cells to increase insulin secretion. This IL-33-ILC2 axis was activated after acute b cell stress but was defective during chronic obesity. Accordingly, IL-33 injections rescued islet function in obese mice. Our findings provide evidence that an immunometabolic crosstalk between isletderived IL-33, ILC2s, and myeloid cells fosters insulin secretion.
INTRODUCTION
Type 2 diabetes occurs when, as a result of obesity and genetic predisposition, pancreatic-islet insulin secretion fails to compensate for the impaired cell response to insulin (i.e., insulin resistance). It is now recognized that the immune system plays an important role in these processes. Indeed, white adipose tissue (WAT) is a site of inflammation characterized by ongoing activation of type 1 immunity during obesity-associated metabolic dysfunction (Donath et al., 2013) . Recent studies suggest a role for resident type 2 immune cells in regulating WAT function and limiting weight gain. Indeed, alternatively activated macrophages, regulatory T cells (Tregs), eosinophils, and group 2 innate lymphoid cells (ILC2s) reside in lean WAT and are altered during obesity . This switch from type 2 to type 1 immunity is supported by findings from studies of two commonly used mouse strains, C57BL/6 and BALB/c, that differ in their immune cell repertoires (for example, see Mills et al., 2000) . The T helper 1 (Th1)-cell-permissive C57BL/6 mice are prone to obesity and insulin resistance, whereas the Th2-cell-permissive BALB/c mice are protected against metabolic complications (Montgomery et al., 2013) .
During obesity and diabetes, pancreatic islets also undergo inflammation. Glucose, saturated fatty acids, and bacterial products stimulate islet-derived chemokines and cytokines, such as interleukin (IL)-1b, that can then recruit and activate macrophages (Bö ni-Schnetzler et al., 2009; Calderon et al., 2015; Eguchi et al., 2012; Ehses et al., 2007; Jourdan et al., 2013; Maedler et al., 2002; Nackiewicz et al., 2014; Richardson et al., 2009) . Accordingly, anti-inflammatory drugs are in development for the treatment of type 2 diabetes (Donath, 2014) . However, islet components of the immune system might also have a beneficial role. Indeed, in experimental b cell ablation models, macrophages promote b cell proliferation and regeneration (Criscimanna et al., 2014; Riley et al., 2015; Xiao et al., 2014) . It remains unknown whether other islet-resident immune cells contribute to the maintenance of b cell function. In this study, we sought to identify immune cells residing in islets and to investigate their role in physiology and disease. By comparing C57BL/6 and BALB/c mice, we identified mesenchymal-cell-derived IL-33 as an islet immunoregulatory feature. We showed that ILC2s were the primary IL-33-responsive cells in islets and that they elicited the production of retinoic acid (RA) by macrophages and dendritic cells via the secretion of IL-13 and colony stimulating factor 2 (Csf2, also known as GM-CSF). In turn, myeloid-cell-derived RA enhanced b cell insulin secretion. This islet IL-33-ILC2-myeloid-cell circuit was activated after acute b cell injury but altered during obesity.
RESULTS

Islet Mesenchymal Cells Produce IL-33
To extend the role of the Th1-Th2 immune paradigm in metabolic homeostasis to islets, we compared BALB/c and C57BL/6 mouse strains. BALB/c mice displayed a more rapid clearance of blood glucose during intra-peritoneal glucose tolerance tests (GTTs), which reveal insulin secretion and receptor activity, than age-matched C57BL/6 mice ( Figure 1A ) with comparable body and adipose mass ( Figure S1A ). Circulating insulin concentrations during GTTs were similar between the groups ( Figure 1B ), despite the fact that BALB/c mice were more insulin sensitive than C57BL/6 mice ( Figure S1B ). Besides, mice showed similar production of the uncoupling protein 1 (UCP1) in their brown adipose tissue ( Figure S1C ). These observations point to increased insulin secretion in BALB/c compared to C57BL/6 mice. Indeed, the insulinogenic index (defined as the ratio of the insulin areas to glucose areas under the curve) during GTTs was higher in BALB/c than in C57BL/6 mice ( Figure 1C ). To confirm a better b cell function, we tested islets ex vivo. Glucose-stimulated insulin secretion (GSIS) was higher in BALB/c than in C57BL/6 islets ( Figure 1D ) that had comparable insulin content ( Figure S1D ). We hypothesized that this difference could be due to the BALB/c mouse immune background and measured expression of genes encoding type 2 immune initiators in islets (McKenzie et al., 2014) . BALB/c islets showed increased expression of Il33 but not of Tslp (thymic stromal lymphopoietin) and Il25 compared to C57BL/6 islets ( Figure 1E ), implying a potential regulatory function for IL-33 in islets.
We next employed an Il33-LacZ gene trap (Il33 Gt/+ ) reporter strain to visualize endogenous Il33 expression in the pancreas (Pichery et al., 2012) . Galactosidase staining revealed constitutive activity of the Il33 promoter in islets and, to a much lesser extent, in the exocrine pancreas (located in some vascular beds) of Il33
Gt/+ mice, and there was no signal in Il33 +/+ wildtype (WT) mice ( Figure 1F and Figure S1E ). To study the cellular origin of IL-33, we sorted islet CD45 + immune and CD45 À remaining cells by flow cytometry. Il33 expression was increased in the CD45 À cells compared to in the immune compartment (Figure 1G) . We next analyzed islets isolated from green fluorescent protein (GFP) IL-33 reporter mice by flow cytometry (Kallert et al., 2017; Oboki et al., 2010) . GFP production was detected in cells that were CD45 À FSC low SSC low and negative for the Epithelial cell adhesion molecule (Epcam), suggesting a nonepithelial phenotype and thus that the cells were not related to an endocrine origin ( Figures 1H and 1I ). The IL-33-GFP + cells were further classified as positive for the mesodermal stem cell antigen-1 (Sca-1) ( Figure 1J ), and they preferentially expressed the mesenchymal marker Vim (vimentin) and not the smooth-muscle-cell marker Acta2 (a-SMA) as opposed to b-cell-enriched and other GFP À subsets ( Figure S1F ). We confirmed that Sca-1 + cells (which had been sorted by flow cytometry), rather than b-cell-enriched and other Sca-1 À cells, were the primary population expressing vimentin in islets ( Figure 1K ). To characterize IL-33 in islets, we stimulated islets with components of a type 2 diabetes milieu. High concentrations of IL-1b, glucose, and the saturated fatty acid palmitate led to increased amounts of IL-33 mRNA and protein in C57BL/6 and BALB/c mouse islets relative to controls (Figure 1L and Figure S1G) , with BALB/c islets overall producing more IL-33 than C57BL/6 islets. Notably, unlike WT controls, IL-33-deficient (Il33 À/À ) mice had undetectable amounts of IL-33 in isolated islet cell lysate ( Figure S1H ). Similar induction of IL-33 was observed in human islets, especially in response to IL-1b ( Figure 1M and Figure S1I ). Taken together, our results prompted us to investigate a possible role for mesenchymal-cell-derived IL-33 as an islet stress-signal-regulating endocrine function.
IL-33-Responsive Cells in Islets Are Resident ILC2s
To determine whether IL-33 plays a local role, we sought to identify resident IL-33-responsive cells within islets. In contrast to (B and C) Immune-cell profiling of islets isolated from C57BL/6 and BALB/c mice. Cell abundance is expressed as (B) percentage of total CD45 + cells and (C) absolute cell number per 1,000 islets. n = 3-5 independent experiments each (see complete gating strategy in Figure S2A ). Figure 2A ). We quantitatively profiled islet-dwelling immune cells of BALB/c and C57BL/6 mice fed a chow diet (see the gating strategy in Figure S2A ). Islets contained an average of six pan-CD45 + immune cells per islet; macrophages were the main immune subset ( Figures 2B and 2C) . BALB/c islets showed increased frequency and cell numbers of specific branches of innate immunity, including ILC2s, dendritic cells, and NK cells, as compared to islets in C57BL/6 mice ( Figures 2B and 2C ). Islets of both strains contained similar amounts of T and B cells and scarce neutrophils and eosinophils ( Figures 2B and 2C ). We identified ILC2s as the primary immune subset producing T1-ST2 on their cell surface within islets (Figure 2D ). Rare Tregs were detectable in islets and did not produce T1-ST2 (data not shown). Of note, T1-ST2 was also not detectable on the surface of mouse insulin + b cells (data not shown).
ILC2s were lineage negative and produced the cell-surface markers CD90.2 and KLRG1 and the transcription factor GATA binding protein 3 (GATA3) ( Figure 2E and Figure S2A ). Islet-resident ILC2s were more frequent among CD45 + cells ( Figure S2B ) and produced higher amounts of T1-ST2 ( Figure 2F ) than ILC2s isolated from the exocrine stroma of the same pancreas, supporting islet ILC2 specificity. Immunofluorescence analyses confirmed the presence of ILC2s located inside ( Figure 2G ) or in the periphery ( Figure S2C ) of islets in Rag2 À/À mouse pancreas. Ex vivo, freshly isolated islets and pancreatic ILC2s sorted by flow cytometry produced type 2 immune cytokines, including IL-5, IL-13, and Csf2, in response to IL-33 and IL-2 (Figure 2H ). ILC3s are also known to produce Csf2 (Mortha et al., 2014) . Compared to frequencies of GATA3 + ILC2s, frequencies of RAR-related orphan receptor (ROR)gt + ILC3s were very low in mouse islets and whole pancreata ( Figure 2E and Figure S2D ), supporting ILC2s as a major source of Csf2 in islets. We next observed that Il33 À/À mice exhibited a 42% ± 8% decrease in ILC2 number in islets in comparison to WT controls ( Figure 2I ). Thus, resident ILC2s are the primary responders to IL-33 in islets, and endogenous IL-33 is required for maintaining the islet ILC2 population.
IL-33 Promotes Insulin Secretion
To examine the effects of IL-33 signaling in islet-resident ILC2s in vivo, we administered either a single dose (acute) or three doses (chronic) of either saline or mouse recombinant IL-33 every other day to C57BL/6 mice fed a chow diet. Although body and adipose mass were not altered ( Figure 3A ), acute and chronic IL-33 treatment decreased fasting blood glucose and enhanced glucose clearance in comparison to saline treatment (controls) ( Figure 3B ). Circulating insulin concentrations during GTTs tended to be boosted after a single injection of IL-33 and reduced upon chronic IL-33 treatment ( Figure 3C ).
Notably, the insulinogenic index was increased upon both acute and chronic IL-33 treatment compared to control treatment (Figure 3D ), pointing to increased insulin secretion and progressively enhanced glucose disposal. Accordingly, islets from IL-33-treated mice dose-dependently showed enhanced GSIS in comparison to controls ( Figure 3E ). IL-33-treated mouse islets also had a better insulin secretion than controls in response to potassium chloride (KCl), known to trigger a robust secretory response ( Figure 3F ). Insulin content was not different between the GSIS groups ( Figures S3A and S3B ). Supporting a role for IL-33 to potentiate b cell function and not mass, IL-33 treatment did not alter b cell area ( Figure 3G ), islet size distribution, and b cell frequency compared to saline groups in this one-week timeframe (Figures S3C and D) . Compared to saline treatment or chronic IL-33 treatment, a single dose of IL-33 (three doses of 0.5 mg administered together, that is 1.5 mg) did not significantly improve glucose tolerance or GSIS, which supports time-dependent improvement of b cell function (Figures S3E and S3F) . We next investigated whether the administration of IL-33 improved the insulin response. IL-33 did not affect insulin sensitivity, as demonstrated by both an insulin-tolerance test (Figure 3H) and hyperinsulinemic-euglycemic clamps ( Figure 3I and Figure S3G ). Tissue glucose uptake was up-regulated in inguinal (Ing)WAT but not in skeletal muscle, epididymal (Epi) WAT, or brown adipose tissue ( Figure 3J ). Considering that IngWAT is the most prone to beiging of its white adipocytes and that IL-33 has been shown to regulate thermogenesis (Brestoff et al., 2015; Lee et al., 2015; Odegaard et al., 2016) , we investigated adipose UCP1 production in our models. Although chronic IL-33 treatment increased Ucp1 expression in EpiWAT ( Figure S3H ), no change in UCP1 was observed in IngWAT of IL-33-treated mice compared to in saline groups (data not shown). Importantly, IL-33 treatment still achieved significant improvement in the glucose clearance in Ucp1 À/À mice compared to controls ( Figure 3K ), indicating that recruitment of UCP1 + beige fat was dispensable for the IL-33-induced metabolic effect. We also performed pancreas perfusions to study in situ GSIS independently of peripheral glucose consumption. In this experimental setting, chronically IL-33-treated mice tended to have increased insulin secretion ( Figure S3I ), further supporting IL-33 as an insulin secretagogue.
To investigate endogenous IL-33 role in metabolism, we characterized IL-33-deficient mice. We did not observe any difference in body and adipose tissue mass, glucose tolerance, and insulin sensitivity in IL-33-Activated ILC2s Promote Insulin Secretion IL-33 administration increased the number of CD45 + cells and more specifically of ILC2s, dendritic cells and eosinophils in islets compared to controls ( Figure 4A and Figures S4A and  S4B ). Although the number and frequency of macrophages were decreased, T and B cell, NK cell, and neutrophil populations were not affected ( Figure 4A and Figure S4A ). We also observed higher mRNA expression of typical ILC2-secreted factors including Il5 (known to mediate eosinophil activation), Il13, and Csf2 in islets from IL-33-treated mice compared to islets in controls ( Figure 4B ). Down-regulation or no change was observed for expression of other type 2 immune genes including Areg (encoding amphiregulin) and type 1 cytokines ( Figure S4C ).
We next investigated whether IL-33-induced insulin secretion was due to the presence of ILC2s. Three doses of IL-33 or saline were administered to BALB/c WT, Rag2 À/À , and ILC2-deficient Figure S4D ). We next treated Rag2
mice with an anti-CD90.2 antibody, which reduces the number of ILC2s (Monticelli et al., 2011) . Anti-CD90.2-treated mouse islets showed a 58 ± 6% decrease in the number of ILC2s (Figure 4E ) and tended to have impaired GSIS compared to Immunoglobulin G (IgG) controls ( Figure 4F ), with no change in insulin content ( Figure S4E ). To further confirm that IL-33 promotes insulin production in an ILC2-dependent manner, Rag2 À/À Il2rg À/À mice were adoptively transferred with pancreatic ILC2s and treated with IL-33. ILC2-reconstituted Rag2 À/À Il2rg À/À mice supported IL-33-induced ILC2 expansion in their pancreata relative to controls (Figure S4F) , without alteration of body and fat mass ( Figure S4G ). ILC2 transfer was sufficient to rescue IL-33-induced improvement in glucose tolerance test ( Figure 4G ) and ex vivo GSIS (Figure 4H) in Rag2
Il2rg
À/À mice, with similar circulating insulin concentrations and islet insulin content ( Figures S4H and S4I ). We next explored whether ILC2s could act directly on b cells by culturing islets with conditioned media of pancreatic ILC2s. We found that ILC2-conditioned media improved islet GSIS compared to unconditioned medium ( Figure 4I ), without affecting insulin content ( Figure S4J ). Collectively, our data indicate that IL-33-induced insulin secretion is not a direct effect of IL-33 on b cells but requires the unique presence of ILC2s and ILC2-secreted factors.
IL-33-ILC2 Axis Elicits RA-Producing Capacities in Islet Myeloid Cells
Islet ILC2s produce IL-13 and Csf2, which are known to imprint RA-producing capacities in macrophages and dendritic cells (Mortha et al., 2014; Yokota et al., 2009) . We sought to determine whether our IL-33-ILC2 axis also promoted RA production in islet resident myeloid cells. Vitamin A is oxidized by alcohol dehydrogenases to yield retinal. Retinal is then converted to RA by aldehyde dehydrogenases (ALDH), the major isoform of which is encoded by Aldh1a2. IL-33 administration dose-dependently up-regulated Aldh1a2 expression in islets compared to in saline controls ( Figure 5A ). We sorted islet macrophages and dendritic cells by flow cytometry from saline-and IL-33-treated mice. Each subset expressed its lineage-characteristic gene, Emr1 (encoding F4/80) or Flt3, respectively, ensuring their identities ( Figure S5A ). Both islet macrophages and dendritic cells showed up-regulation of Aldh1a2 mRNA in IL-33-treated mice compared to in controls ( Figure 5B ). We next measured the relative ALDH activity in islet individual myeloid cells with a fluorescent substrate for ALDH. Islets treated with ALDH inhibitory diethylaminobenzaldehyde were used as a negative control. According to the morphological analysis of islet macrophages, we identified two distinct populations, R1 and R2 ( Figure S5B ). IL-33 treatment markedly increased ALDH activity in islet R1 macrophages and dendritic cells compared to in controls ( Figures 5C and 5D ). Although the frequency of granular R2 macrophages was increased in IL-33-treated mice relative to in controls (Figure S5C ), R2 macrophage ALDH activity was not inhibited by diethylaminobenzaldehyde, an observation that points toward cell autofluorescence ( Figure S5D ). Enhanced ALDH activity in both R1 macrophages and dendritic cells was observed in islets isolated from Rag2 À/À mice but not Rag2
treatment with IL-33, suggesting that IL-33-induced myeloid RA production is ILC2-dependent ( Figures 5E and 5F ).
To identify the ILC2-secreted mediators responsible for increased ALDH activity in myeloid cells during IL-33 treatment, we tested the effect of IL-13 and Csf2 in vitro. We found that these two molecules together up-regulated the expression of Aldh1a2 in islet macrophages sorted by flow cytometry (Figure 5G ) and in bone marrow-derived dendritic cells ( Figure 5H ). Of note, recombinant IL-33 did not induce Aldh1a2 in myeloid cells in vitro (data not shown). Islets cultured in the presence of ILC2-conditioned media showed increased Aldh1a2 expression in comparison to islets cultured in control medium; this increased expression was hampered by the presence of combined anti-IL-13 and anti-Csf2 neutralizing antibodies ( Figure 5I ). Besides, islets showed increased Aldh1a2 expression compared to controls when stimulated with IL-33 and IL-2 in vitro, suggesting that resident IL-33-responsive ILC2s cells polarize neighboring myeloid cells ( Figure 5J ). Accordingly, Il33 À/À mice displayed reduced ALDH activity in islet resident dendritic cells ( Figure 5K ) but not macrophages ( Figure S5E ) compared to WT littermates. Collectively, these data support that IL-33-activated ILC2s imprint islet resident myeloid cells with RA-producing capacities in IL-13-and Csf2-dependent ways. Dendritic cells but not macrophages are dependent on endogenous IL-33 to sustain their physiological ALDH activity in islets.
IL-33-Mediated Insulin Secretion Is Dependent on Vitamin A
We next investigated whether IL-33-induced insulin secretion is dependent on RA signaling. The pharmaceutical form of RA, all-trans RA, induced insulin secretion in islets in vitro, with insulin content similar to that of DMSO controls ( Figure 6A and Figure S6A ). Many RA biological activities are mediated by RA receptors (RARa, RARb, and RARg) or retinoic X receptor (RXRa), whose gene expression can be self-induced (Wu et al., 1992) . We observed that all-trans RA exclusively up-regulated the expression of Rarb (which encodes RARb) in islets compared to controls ( Figure 6B ). Accordingly, ILC2-conditioned media failed to increase insulin secretion in islets cultured in the presence of the synthetic RARb receptor antagonist LE135 in comparison to control islets, and islet insulin content during GSIS was similar in each group ( Figure 6C and Figure S6B ). We next conducted a vitamin A deprivation study. To avoid any developmental confounding effects, adult mice were given the diet for 10 weeks. Vitamin A deprivation did not alter body weight nor insulin sensitivity compared to the control chow diet (Figures S6C and S6D ). All mice were chronically treated with IL-33 or saline. Notably, vitamin A deficiency did not hinder IL-33-mediated type 2 immunity with similar islet ILC2 and eosinophil numbers between the groups ( Figure 6D ). In contrast, IL-33 administration failed to induce Aldh1a2 expression in islets from vitamin-A-deprived mice compared to mice fed the corresponding chow diet and the saline groups ( Figure 6E ). Reduced ALDH activity was confirmed in islet dendritic cells and to a lesser extent in R1 macrophages from IL-33-treated vitamin A deprived versus chow diet mice ( Figure S6E ). We did not observe any difference in blood glucose or plasma insulin concentrations during GTTs between the groups ( Figure S6F ). However, the insulinogenic index was significantly increased in IL-33-treated compared to in saline-treated chow diet mice but not in vitamin-A-deprived mice ( Figure 6F ), suggesting that IL-33-induced insulin secretion is reduced in the absence of vitamin A. To further investigate the contribution of vitamin A, we performed ex vivo experiments with islets. IL-33 treatment increased insulin secretion during both GSIS and KCl-induced insulin secretion in islets from mice fed a control chow diet but not from vitamin-A-deprived mice compared to mice in saline groups ( Figures 6G and 6H) , without a change in insulin content ( Figures S6G and S6H) . Therefore, enhancement of b cell function by IL-33 is dependent on dietary vitamin A and its conversion into RA.
Chronic versus Acute Islet Inflammation Regulates the IL-33-ILC2 Axis
To investigate the role of the IL-33-ILC2 axis in a pathological context, mice were fed a chow or high-fat diet. At 3 months, obese mice showed increased body weight and impaired GTTs ( Figures S7A and S7B) . Notably, obesity was associated with increased plasma insulin concentrations and the absence of glucose-induced insulin production at 15 min compared to baseline ( Figure S7C ). In comparison to those from controls, islets isolated from obese mice showed a progressive decrease in Il33 expression and the amount of IL-33 ( Figures 7A and 7B) . Accordingly, obese mouse islets displayed decreased frequency and number of ILC2s compared to chow diet controls ( Figure 7C ), together with a late decrease in islet Aldh1a2 expression (Figure 7D) . 7 month-obese mice treated with three doses of IL-33 showed a drastic improvement in glucose clearance during GTTs ( Figure 7E ), despite no change in body and WAT weights ( Figure S7D ). IL-33-treated mice overall had lower insulin production than the baseline but showed rescued GSIS at 15 min during GTTs ( Figure 7F ). Of note, obesity did not hinder IL-33-mediated accumulation of ILC2s or, subsequently, eosinophils in islets of IL-33-treated mice compared to saline controls ( Figure S7E ).
We next selectively induced b cell injury with a single high dose of streptozotocin (STZ) ( Figure S7F ). STZ induced a diabetic phenotype characterized by altered glycaemia and insulinaemia compared to buffer-treated mice (data not shown). STZ-treated mice showed increased islet Il33 expression ( Figure 7G ) and a more diffuse galactosidase staining than buffer-treated controls ( Figure S7G ), pointing towards a more active Il33 promoter. Accordingly, STZ treatment increased the frequency and number of ILC2s in islets compared to in controls ( Figure 7H ), and increased islet Aldh1a2 expression ( Figure 7I ). IL-33 treatment in STZ-induced diabetic mice improved fasting glycemia and prevented further body weight loss compared to in controls (Figure 7J) , with a tendency towards increased fasting plasma insulin concentrations on day 9 ( Figure S7H ) and larger EpiWAT (Figure S7I) . In contrast, administration of the ILC2-depleting anti-CD90.2 antibody in STZ-induced diabetic Rag2 À/À mice tended to worsen fasting glycemia compared to IgG controls ( Figure 7K ). We did not detect any difference in glycemia when Il33 À/À and WT littermates were treated with a similar STZ dose (data not shown). Taken together, our results show that the IL-33-ILC2 axis is defective in islets during obesity and is activated following acute b cell stress. ILC2s might not only boost insulin secretion but also contribute to b cell recovery following injury.
DISCUSSION
Our work has established a role for type 2 immunity in the regulation of islet physiology orchestrated by IL-33. Many studies described IL-33 production in mouse tissues at steady state, including in epithelial cells of barrier tissues or endothelial cells in adipose tissue (Liew et al., 2016) . In patients suffering from chronic pancreatitis, IL-33 was mainly produced by activated pancreatic stellate cells (Masamune et al., 2010) . Here, using two different models of IL-33 reporter mice, we identified IL-33-producing cells as Sca-1 + vimentin + mesenchymal cells located inside pancreatic islets. Of note, due to b cell autofluorescence, we cannot exclude the possibility that some IL-33 was produced in b cells in our Il33 gfp/wt mice. In mouse and human islets, IL-33 production was increased upon stimulation with components of a diabetic milieu, proposing IL-33 as a stress signal in islets. Indeed, designated as an ''alarmin,'' IL-33 is usually released after cell injury to alert the immune system and initiate repair processes (Liew et al., 2016) . We detected IL-33 only in islet cell lysate and not in the supernatant. This argues in favor of IL-33 nuclear localization and the requirement for cell death for its proper release. Alternatively, detection of IL-33 in islet cell supernatant might be hindered by its low concentration and rapid inactivation (Liew et al., 2016) . Although the role of islet mesenchymal cells remains to be explored, we showed that IL-33 promotes b cell function in chow diet-fed mice. In obese mice, IL-33 injections rescued GSIS during GTTs relative to controls. Conversely, islets from Il33 À/À mice displayed impaired GSIS compared to WT littermates. Supporting our findings, mice lacking IL-33 receptor T1-ST2 develop hyperglycemia and impaired insulin secretion when fed a high-fat diet (Miller et al., 2010) . In contrast to published data linking IL-33 deficiency to obesity, glucose intolerance (Brestoff et al., 2015) , and thermogenesis defect ( Islets treated with the ALDH inhibitory diethylaminobenzaldehyde (DEAB) were used as a negative control.
(E and F) Frequencies of (E) ALDH + R1 Macs and (F) ALDH + DCs in islets isolated from saline-and IL-33-treated BALB/c Rag2 À/À and Rag2
cohorts.
(legend continued on next page) chow diet. These divergent findings might arise from variations in dietary fat and sucrose content and the use in our study of littermate controls backcrossed on a pure genetic background.
The protective role of IL-33 in obesity has been widely attributed to its modulation of WAT inflammation towards type 2 immunity, which could promote insulin sensitivity (Kolodin et al., (G and H) Expression of Aldh1a2 in (G) islet macrophages (n = 4 independent experiments) or (H) bone-marrow-derived DCs (BM-DCs; n = 10 from three independent experiments) stimulated with IL-13 and Csf2. (I) Expression of Aldh1a2 in islets treated in vitro with ILC2-conditioned media (CM) or control medium with or without anti(a)-IL-13 and a-Csf2 neutralizing antibodies. n = 8 or 9 per group from three independent experiments. (J) Expression of Aldh1a2 in islets isolated from BALB/c mice and stimulated in vitro with IL-2 and IL-33. n = 9 per group from three independent experiments. (K) Frequencies of ALDH + DCs in islets isolated from Il33 +/+ and Il33 À/À littermates. n = 3 cohorts.
Data are represented as the means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001; statistical significance (p) was determined by one-way ANOVA (A and C-H) and twoway ANOVA (I and K) with Bonferroni's post-hoc test and Student's t test (B and J). See also Figure S5 . Frequencies and absolute numbers of ILC2s and eosinophils in islets (n = 3 from three cohorts), (E) expression of Aldh1a2 in islets (n = 6-10 from each of four cohorts) and (F) insulinogenic index during GTTs (n = 11-13 mice from each of three cohorts) of saline-and IL-33-treated mice fed a CD or VAD. (G and H) Insulin release during (G) GSIS and (H) KClstimulated insulin-secretion assays from islets isolated from saline-and IL-33-treated mice fed a CD or VAD. n = 8 or 9 from each of two cohorts. Data are represented as the means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001; statistical significance (p) was determined by one-way ANOVA (E and F) and twoway ANOVA (A-C, G, and H) with Bonferroni's post-hoc test. See also Figure S6 . 2015; Miller et al., 2010; Molofsky et al., 2013; Molofsky et al., 2015; Vasanthakumar et al., 2015) . In mice with genetic or dietinduced obesity, IL-33 treatment improved glucose homeostasis compared to in controls. However, this phenotype was not associated with enhanced insulin sensitivity (Miller et al., 2010; Vasanthakumar et al., 2015) . Here, we also showed that IL-33 treatment in chow diet mice improved glycemia independently of insulin sensitivity. Recently, IL-33 was shown to elicit WAT beiging and regulate the splicing of Ucp1 mRNA (Brestoff et al., 2015; Lee et al., 2015; Odegaard et al., 2016) . Beige cells have the capacity to consume glucose to produce heat (Kajimura et al., 2015) . Although glucose uptake was increased in IngWAT of IL-33-treated mice, chronic IL-33 treatment failed to induce UCP1 protein in WAT compared to in controls, suggesting that our experimental settings are not yet sufficient to stimulate the growth of functional beige fat. Indeed, reports of IL-33-mediated beiging have been based on daily IL-33 injections for more than a week (Brestoff et al., 2015; Lee et al., 2015) . Treatment of UCP1-deficient mice confirmed that IL-33 metabolic effects do not rely on recruitment of beige adipocytes to clear the blood glucose. Thus, IL-33 treatment in chow diet-fed mice mainly lowers glycemia by rapid stimulation of insulin secretion in b cells, independently of changes in both insulin sensitivity and adipose beiging. The fact that chronic IL-33 treatment tends to lower insulin concentrations during GTTs might be in response to alternative IL-33 glucose-lowering effects, including glucose consumption by an increased number of activated immune cells. IL-33 signals through the T1-ST2 receptor, which is mainly produced in immune cells. Although IL-33 induces oxidative stress in the MIN6 b cell line (Hasnain et al., 2014) , we did not detect T1-ST2 on the surface of mouse primary b cells but rather detected it on resident immune cells. Although an extensive body of literature focuses on autoimmune diabetic mouse models, there are only a limited number of studies addressing the nature of islet immune cells in WT mice at steady state or in the context of type 2 diabetes. Differences in the methods used to isolate islets could affect immune-cell purity, number, and surface markers. Likewise, the number of islets (from one mouse or pools of mice) could greatly influence the outcome because the number of immune cells ranges from two to ten per islet (Calderon et al., 2015; Calderon et al., 2008; Cucak et al., 2014; Ehses et al., 2007) . In our study, we used clean, handpicked islets that were isolated from pools of mice. We confirmed that macrophages are the major immune-cell population existing within normal islets. Yet we also noticed ILC2s, dendritic cells, and NK cells that were more abundant in BALB/c mice than in C57BL/6 mice. Therein, ILC2s located inside and at the periphery of islets were the primary IL-33-responsive cells likely to influence b cell function.
ILC2s are rare yet potent resident cells that mediate tissue protection and repair processes (McKenzie et al., 2014) . Our work further extends the understanding of their function to include endocrine regulation. IL-33 treatment in Rag2 À/À mice,
Rag2
À/À Il2rg À/À mice, and Rag2
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À/À mice adoptively transferred with ILC2s confirmed that IL-33 does not act directly on b cells but is dependent on the presence of ILC2s and ILC2-secreted factors to promote insulin secretion. IL-33 administration led to a massive accumulation of ILC2s and, subsequently, dendritic cells and eosinophils. Thus, we cannot rule out a possible role for eosinophils in IL-33-mediated metabolic benefits. The IL-33-ILC2 axis also contributed to b cell protection in the context of obesity-and STZ-induced b cell stress, supporting a functional role for this axis. Similar to adipose tissue (Molofsky et al., 2013) , obesity was associated with a loss of islet ILC2s. This could be explained in part by the phenotypic plasticity that ILC2s exhibit in response to inflammatory cues, including IL-1b (Ohne et al., 2016) , that are elevated during type 2 diabetes in islets (Donath et al., 2013) . Islet ILC2s produced IL-13 and Csf2 and thereby induced RAproducing capacities in approximately 30% of resident dendritic cells and 5% of macrophages under physiological conditions. These percentages were markedly increased after IL-33 treatment but diminished (for dendritic cells) in IL-33-deficient mice. Similar crosstalk has been described in the mouse intestine. Microbiota-driven IL-1b production by macrophages promotes the release of Csf2 by ILC3s, and this release in turn regulates RA production in phagocytes and leads to local Treg homeostasis (Mortha et al., 2014) . Our study reveals that similar interactions between islet ILC2s and myeloid cells boost insulin secretion, and these interactions are thus not related to classical immune responses.
Vitamin A or RA-related gene deficiencies block the development of fetal pancreatic islets and abrogate the maintenance of b cell mass and function during adulthood (Brun et al., 2015; Chertow et al., 1987; Martín et al., 2005; Matthews et al., 2004; Pé rez et al., 2013; Trasino et al., 2016) . We identified resident macrophages and especially dendritic cells as endogenous RA producers in islets. We gave a vitamin-A-deficient diet to adult mice to avoid any developmental issues. In contradiction to published data (Trasino et al., 2016) , vitamin-Adeprived mice did not show impaired glucose homeostasis per se. However, we observed that IL-33 treatment did not promote b cell function in vitamin-A-deprived mice, in contrast to IL-33 treatment in control mice, supporting the view that IL-33-induced insulin secretion requires vitamin A and its conversion to RA.
In conclusion, our study has identified immunometabolic crosstalk within islets and shown that this crosstalk is initiated by IL-33-releasing mesenchymal cells and leads to an insulin secretagogue effect. IL-33 acts on resident ILC2s that elicit RA-producing capacities in myeloid cells to support insulin secretion. This work represents a step toward improving our understanding of islet resident immune cells and showing that ILC2s can influence b cell physiology. In addition to blocking pro-inflammatory type 1 immunity, selective activation of type 2 immunity could offer therapeutic avenues for immunotherapies in patients suffering from diabetes.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
METHOD DETAILS
Mouse pancreatic islets To isolate mouse islets, pancreata were perfused through the common bile duct with a HBSS collagenase solution (1.4 g/L; collagenase type 4 Worthington) and digested in the same solution in a 37 C water bath for 26-28 min. After shaking for 15 seconds, pancreata were washed three times with HBSS supplemented with 0.5% bovine serum albumin (BSA) and filtrated through 500 mm and 70 mm cell strainers (Corning). Islets were retained on the 70 mm cell strainer while the cell mixture passing through the 70 mm cell strainer represented the exocrine stoma. Islets from the same condition were double handpicked and pooled into a Petri dish with RPMI-1640 (GIBCO) containing 11.1 mM glucose, 100 units/ml penicillin, 100 mg/ml streptomycin, 2 mM Glutamax, 50 mg/ml gentamycin, 10 mg/ml Fungison and 10% FCS (Invitrogen). Islets were used directly for flow cytometry analysis, RNA isolation or cell culture in humid environment containing 5% CO 2 .
In vitro islet treatment For Il33 gene expression analyses, 80 handpicked mouse or 2 mL of human islet preparation were cultured on extracellular matrixcoated 24-well plates and treated overnight with recombinant mouse or human IL-1b (10 ng/mL; R&D systems), 33.3 mM of glucose, low endotoxin BSA (Sigma-Aldrich) and/or BSA-coated sodium palmitate (0.5mM; Sigma-Aldrich) before lysis for RNA isolation. For IL-33 protein measurement, 200 handpicked mouse islets or 4 mL of human islet preparation were cultured in suspension in a 96-well plate with similar treatments. After 24h culture, islet-free supernatants were stored at -80 C until analysis. For extraction of the wholeprotein fraction of islets, samples were homogenized in lysis buffer (20mM Tris pH 7.5; 150mM NaCl; 10% glycerol; 1% Triton X-100; 1% Na 3 VO 4 ; 1% NaF; 0.5% PMSF and 1 mM EDTA) supplemented with a protease inhibitor cocktail (Roche). When indicated, mouse cultured islets were treated with 1 mM of all-trans retinoic acid (R2625; Sigma-Aldrich) for 24h, 2 mM of the synthetic RARb receptor antagonist LE135 (SML0809; Sigma-Aldrich) for 24h or the neutralizing anti-mouse IL-13 (0.05 mg/mL) and anti-mouse GM-CSF (1.25 mg/mL) Functional Grade Purified antibodies and corresponding isotypes for 48h (Thermo Fisher Scientific). 100 BALB/c islets were stimulated ex vivo with IL-2 and IL-33 (10 ng/mg; Thermo Fisher Scientific) for 72h.
In vitro glucose-and potassium chloride-stimulated insulin secretion assays For ex vivo insulin secretion stimulation assays, 20 mouse islets were cultured for 24h and then pre-incubated for 30 min in modified Krebs-Ringer bicarbonate buffer (KRB; 115 mM NaCl, 4.7 mM KCl, 2.6 mM CaCl 2 2H 2 O, 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 2H 2 O, 10 mM HEPES, 0.5% bovine serum albumin, pH 7.4) containing 2.8 mM glucose. KRB was then replaced by KRB with 2.8 mM glucose and collected after 1h to determine the basal insulin release. This was followed by 1h incubation in KRB with 16.7 mM glucose (GSIS) or with KRB with 2.8 mM glucose supplemented with 25 mM of potassium chloride to determine the glucose-or potassium chloride-stimulated insulin release. After supernatant collection, islet protein content was extracted with 0.18 N hydrochloride acid in 70% ethanol to measure insulin content (20 islets in 500 mL). For GSIS following an in vitro treatment, islets were resting for 48h and then treated for 24h with all-trans retinoic acid or 48h with ILC2-conditioned or control media before GSIS.
In vivo glucose and insulin tolerance tests For glucose tolerance tests (GTTs), mice were fasted for 6h in the morning and then injected with glucose (2 g per kg of body weight) intraperitoneally (i.p.). For insulin tolerance tests, mice were fasted for 3h in the morning and i.p. injected with human insulin (Novorapid, Novo Nordisk) (1U per kg of body weight) diluted in saline solution. Blood glucose was sampled from the mouse tail vein every 15-30 min following glucose or insulin injection and measured using a glucometer (Freestyle, Abbott Diabetes Care Inc.).
Glucose clamp studies
Glucose clamp studies were performed in freely moving mice as previously described (Wueest et al., 2014) . Steady state glucose infusion rate was calculated once glucose infusion reached a constant rate with blood glucose concentrations of 5 mmol/l (80-90 min after the start of insulin infusion). Thereafter, blood glucose concentration was kept constant at 5 mmol/l for 15-20 min and glucose infusion rate was calculated. Glucose infusion rate and hepatic glucose production were calculated as previously described (Wueest et al., 2014) . In order to assess tissue specific glucose uptake, a bolus (10 mCi) of 2-[1-14C] deoxyglucose was administered via catheter at the end of the steady state period. Blood was sampled 2, 15, 25, and 35 min after bolus delivery. Area under the curve of disappearing plasma 2-[1-14C] deoxyglucose was used together with tissue-concentration of phosphorylated 2-[1-14C] deoxyglucose to calculate glucose uptake.
In vivo IL-33 and anti-CD90.2 antibody treatments Carrier-free recombinant murine IL-33 (Biolegend) was administered in 100 mL sterile saline by i.p. injection for one or three doses every other day at 500 ng per dose in chow diet mice. Mice fed a high fat diet received either saline or IL-33 for three doses every other day at 20 mg per kg of body weight. Metabolic tests were performed the day after the last injection. Mice were sacrificed one or two days after the last injection. For streptozotocin-induced diabetic C57BL/6 mice, only hyperglycemic mice (i.e., fasting blood glucose > 11 mM) were injected with IL-33 (starting from day 6 after streptozotocin injection). Anti-CD90.2 (30-H12; 250 mg) antibody or corresponding IgG2b (RTK4530) (Biolegend) was administered in 125 mL sterile Phosphate Buffer Solution by i.p. injection twice every other day into BALB/c Rag2 -/-mice or streptozotocin-induced diabetic C57BL/6 Rag2 -/-mice (starting from day 6 after streptozotocin injection).
Flow cytometry
Clean handpicked islets were isolated and pooled together from at least 3 mice per condition. To obtain single cells, islets were gently dispersed with a 0.0125% trypsin-EDTA (GIBCO) solution for 2 min in a 37 C water bath, washed with cold FACS buffer (PBS with 0.5% BSA and 5 mM EDTA), centrifuged at 300 x g, 4 C for 5 min and resuspended in FACS buffer. After 15 min incubation with an Fc blocker (93; Thermo Fisher Scientific), single islet cells were stained with the appropriate antibodies or isotypes for 30 min at 4 C in the dark. The following antibodies were used: anti-CD45 (30-F11), anti-F4/80 (BM8), anti-CD11c (N418), anti-I-A/I-E (MHC-II) (M5/ 114.15.2), anti-CD3 (145-2C11), anti-B220 (RA3-6B2), anti-NKp46 (29A1.4), anti-Ly6G (1A8 -Ly6g), anti-CD90.2 (53-2.1), anti-KLRG1 (2F1), anti-CD103 (2E7) and anti-Sca-1 (D7) (from Thermo Fisher Scientific or Biolegend); anti-SIGLEC-F (E50-2440) (from BD bioscience) and anti-T1-ST2 (DJ8) (from mdbioproducts). ILC2 and ILC3 were identified based on the absence of PE-labeled lineage markers: anti-F4/80 (BM8), anti-CD11b (M1/70), anti-CD11c (N418), anti-Ly6G (RB6-8C5), anti-CD3 (145-2C11), anti-CD4 (GK1.5), anti-CD8a (53-6.7), anti-TCR beta (H57-597), anti-gamma delta TCR (eBioGL3), anti-CD19 (eBio1D3), anti-CD45R (RA3-6B2), anti-NKp46 (29A1.4), anti-NK1.1 (PK136) for C57BL/6 mice, anti-CD49b (DX5) for BALB/c mice and anti-Ter119 (Ter119) (all from Thermo Fisher Scientific). Anti-NKp46 was excluded from the lineage cocktail for the comparative study of ILC2/ILC3. DAPI + cells and doublet were excluded from all analyses. For the detection of transcription factors, cells were fixed and stained using the Foxp3-staining kit (Thermo Fisher Scientific) according to the manufacturer's instructions and using anti-GATA3 (TWAJ) and anti-RORg(t) (B2D) antibodies and a fixable viability dye (all from Thermo Fisher Scientific). For quantification of b and a cells in islets, cells were fixed and stained with anti-insulin (C27C9; Cell Signaling) and biotinylated anti-glucagon antibodies (Abcam). Multiparameter analyses were performed on a LSR-Fortessa flow cytometer (BD Bioscience) and analyzed with FlowJo software (Tree Star). For islet cell fraction sorting, anti-CD45 (30-F11) and anti-Sca-1 (D7) antibodies were used (from Thermo Fisher Scientific) to detect immune and mesenchymal cell populations, respectively. The b cell-enriched cell fraction was defined as cells showing a very high FSC-SSC profile (due to b cell insulin granularity). Cells were sort-purified with a FACS ARIA III cell sorter (BD Biosciences) using FACS Diva software (BD Biosciences).
Aldehyde dehydrogenase activity
Aldehyde dehydrogenase (ALDH) activity was determined using the ALDEFLUOR staining kit (StemCell Technologies) according to the manufacturer's instructions. Briefly, dispersed islet cells were divided into two tubes: one test and one control. In the control tube, ALDH inhibitor diethylaminobenzaldehyde (DEAB) was added and incubated for 15 min at 37 C. Then, fluorescent ALDH reagent was added in both tubes for 35 min at 37 C. Cells were washed twice and incubated with appropriate antibodies for FACS analysis.
Sort-purification of pancreatic ILC2
Whole pancreata of C57BL/6 mice were collected and pancreatic lymph nodes were removed under a stereomicroscope. Pancreata were cut into small pieces with razor blades and washed in fresh ice cold PBS. Pancreas pieces were incubated in 1.5 mL DMEM (GIBCO) containing 1 mg/ml Collagenase D (Roche) and 0.025 mg/mL DNAse I (Roche) at 37 C for 15 min. After incubation, pancreas pieces were washed with DMEM and supernatant was collected and passed through a 70 mm cell strainer (Corning). These steps were repeated 3 to 4 times. Isolated cells were washed with PBS and purified using a Percoll (GE Healthcare) gradient (40%/80%) at 20 C and 630 x g for 30 min. Cells of the interphase were collected and washed with PBS containing 3% FCS (Gibco Life Technologies). Pancreatic ILC2 identified as Lin-CD90.2 + Sca-1 + CD25 + cells were sorted with a FACS Aria (BD Biosciences) and re-analysis showed that cell purity was > 95%.
In vitro stimulation of pancreatic ILC2 For ILC2-conditioned media, approximately 2000 ILC2 were stimulated for 72h in RPMI containing 10% FBS with recombinant mouse IL-33 (10 ng/mL; Biolegend) and IL-2 (10 ng/mL; Thermo Fisher Scientific) in 96-well round bottom plates (Falcon) at 37 C and 10% CO 2 . Supernatant was recovered and stored at -80 C for further experiments. For control medium, cell-free RPMI containing 10% FBS supplemented with the cytokines was incubated for 72h in the same conditions.
ILC2 transfer
Pancreatic ILC2 were purified from C57BL/6 mice that received i.p. three doses of IL-33 (500ng) every other day. 3 x 10 5 cells or PBS were immediately transferred to recipient Rag2 -/-Il2rg -/-mice by a single intravenous injection. 2h later and the next
